Drug Resistance in the Treatment of Colorectal Cancer
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 5721
Special Issue Editors
2. Digestive Surgery Department, University Hospital of Limoges, 87000 Limoges, France
Interests: colorectal cancer stem cells; resistance; epithelial–Mesenchymal transition; autophagy
2. Digestive Surgery Department, University Hospital of Limoges, 87000 Limoges, France
Interests: colorectal cancer; resistance
Special Issue Information
Dear Colleagues,
Colorectal cancer is the 3rd most common cancer worldwide, with a mean age of diagnosis at around 71 years old. Recent data suggest that there is an increased incidence of cases in young people. Moreover, despite improvement in prognosis thanks to targeted therapies over the past two decades, the rate of recurrence or resistance to treatment remains high. For instance, for stage 3, this rate reaches 30%, despite well-conducted curative treatment. Its complexity is in part related to the heterogeneity present within the tumor. This is linked to the presence of a set of stem cells that are able to initiate tumor formation, called cancer-initiating cells (CICs). In addition, tumor aggressiveness and resistance to treatments are not only driven by these CICs but also by the crosstalk with the tumor microenvironment (TME—i.e., fibroblasts, adhesion cells, endothelial cells, and immune system cells). The latter may be mediated by direct contact, or by transporters such as extracellular vesicle secretion, leading to an increased cancer biology complexity.
Therefore, this Special Issue will consider articles on all types of research on the biology of colorectal cancer stem cells and on their interconnection with the TME, with a focus on aggressiveness, dissemination, resistance to specific treatments and the potential presence of treatment and diagnosis biomarkers of these features.
Dr. Niki Christou
Dr. Muriel Mathonnet
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug resistance
- colorectal cancer
- treatment
- cancer initiating cells
- cancer stem cells
- biomarkers
- microenvironment
- basis of therapeutic management
